The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023, marking a transformation aimed at strengthening its market position as a translational solutions provider. Revvity serves pharmaceutical and biotech, clinical labs, academia, and governments worldwide.
Cyborg Score Rationale
With a market capitalization of $11.8B and trailing twelve month revenue of $2.86B, Revvity demonstrates solid financial performance. The company benefits from a broad customer base across pharma, diagnostics, and academic research, though it faces intense competition from larger diversified life sciences players.
Top Insights
Q4 2025 earnings beat analyst expectations, with analysts boosting forecasts following the results
Recent acquisition of ACD/Labs completed in November 2025 demonstrates continued strategic portfolio expansion
Medical diagnosis equipment represents 54.5% of revenue while analytical tools and instruments comprise 45.5%, providing balanced diversification
Significant geographic diversity with US at 39.8%, China at 16.3%, UK at 4.1%, and other regions at 39.8% of revenue
Named Competitors
Thermo Fisher Scientific — Analytical instrumentation and research tools
Agilent Technologies — Life sciences and diagnostics instrumentation
Danaher Corporation — Laboratory automation and detection technologies
Abbott Diagnostics — Newborn screening and prenatal diagnostics
Roche Diagnostics — In vitro diagnostics and testing solutions